<?xml version="1.0" encoding="UTF-8"?><?xml-stylesheet type="text/xsl" href="static/style.xsl"?><OAI-PMH xmlns="http://www.openarchives.org/OAI/2.0/" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:schemaLocation="http://www.openarchives.org/OAI/2.0/ http://www.openarchives.org/OAI/2.0/OAI-PMH.xsd"><responseDate>2026-04-20T04:02:16Z</responseDate><request verb="GetRecord" identifier="oai:www.recercat.cat:2072/429641" metadataPrefix="qdc">https://recercat.cat/oai/request</request><GetRecord><record><header><identifier>oai:recercat.cat:2072/429641</identifier><datestamp>2026-04-14T03:13:36Z</datestamp><setSpec>com_2072_98</setSpec><setSpec>col_2072_378192</setSpec></header><metadata><qdc:qualifieddc xmlns:qdc="http://dspace.org/qualifieddc/" xmlns:dc="http://purl.org/dc/elements/1.1/" xmlns:dcterms="http://purl.org/dc/terms/" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:doc="http://www.lyncode.com/xoai" xsi:schemaLocation="http://purl.org/dc/elements/1.1/ http://dublincore.org/schemas/xmls/qdc/2006/01/06/dc.xsd http://purl.org/dc/terms/ http://dublincore.org/schemas/xmls/qdc/2006/01/06/dcterms.xsd http://dspace.org/qualifieddc/ http://www.ukoln.ac.uk/metadata/dcmi/xmlschema/qualifieddc.xsd">
   <dc:title>Prognostic value of the Stanniocalcin-2/PAPP-A/IGFBP-4 axis in ST-segment elevation myocardial infarction</dc:title>
   <dc:creator>Cediel, Germán</dc:creator>
   <dc:creator>Rueda, Ferran</dc:creator>
   <dc:creator>Oxvig, Claus</dc:creator>
   <dc:creator>Oliveras, Teresa</dc:creator>
   <dc:creator>Labata, Carlos</dc:creator>
   <dc:creator>De Diego, Oriol</dc:creator>
   <dc:creator>Ferrer Massot, Marc</dc:creator>
   <dc:creator>Aranda-Nevado, M. Cruz</dc:creator>
   <dc:creator>Serra-Gregori, Judith</dc:creator>
   <dc:creator>Núñez, Julio</dc:creator>
   <dc:creator>Garcia Garcia, Cosme</dc:creator>
   <dc:creator>Bayés-Genís, Antoni</dc:creator>
   <dc:creator>Universitat Autònoma de Barcelona</dc:creator>
   <dc:subject>STEMI</dc:subject>
   <dc:subject>Prognosis</dc:subject>
   <dc:subject>Stanniocalcin-2</dc:subject>
   <dc:subject>PAPP-A</dc:subject>
   <dc:subject>IGFBP-4</dc:subject>
   <dcterms:abstract>Altres ajuts: Fundació La MARATÓ de TV3 (201502 and 201516)</dcterms:abstract>
   <dcterms:abstract>The aim of the present study was to evaluate the prognostic value of the Stanniocalcin-2/PAPP-A/IGFBP-4 axis in patients with ST-segment elevation myocardial infarction (STEMI). Observational cohort study performed in 1085 consecutive STEMI patients treated with early reperfusion between February 2011 and August 2014. Stanniocalcin-2, PAPP-A, and IGFBP-4 were measured using state-of-the art immunoassays. The primary outcome was the composite endpoint of all-cause mortality and readmission due to heart failure (HF). Median follow-up was 3.3 years (IQR 1.0-3.7), during which 176 patients (16.2%) presented a composite endpoint. Multivariable cox regression analysis revealed that Stanniocalcin-2 (HR 2.06; 95% CI 1.13-3.75; p = 0.018), IGFBP-4 (HR 1.73; 95% CI 1.14-2.64; p = 0.010), Killip-Kimball class III-IV (HR 1.40; 95% CI 1.13-1.74; p = 0.002), NT-ProBNP (HR 1.21; 95% CI 1.07-1.37; p = 0.002), age (HR 1.06; 95% CI 1.04-1.08; p &lt; 0.001) and left ventricular ejection fraction (HR 0.97; 95% CI 0.95-0.98; p &lt; 0.001) were independent predictors of the composite endpoint. A model containing Stanniocalcin-2 and IGFBP-4 on top of clinical variables significantly improved C-index discrimination (p = 0.036). Stanniocalcin-2 was also identified as independent predictor of all-cause mortality (HR 2.23; 95% CI 1.16-4.29; p = 0.017) and readmission due to HF (HR 3.42; 95% CI 1.22-9.60; p = 0.020). In STEMI patients, Stanniocalcin-2 and IGFBP-4 emerged as independent predictors of all-cause death and readmission due to HF. The Stanniocalcin-2/PAPP-A/IGFBP-4 axis exhibits a significant role in STEMI risk stratification.</dcterms:abstract>
   <dcterms:issued>2018</dcterms:issued>
   <dc:type>Article</dc:type>
   <dc:relation>Ministerio de Educación y Ciencia SAF2014-59892</dc:relation>
   <dc:relation>Ministerio de Economía y Competitividad CB16/11/00403</dc:relation>
   <dc:relation>Cardiovascular diabetology ; Vol. 17 (april 2018)</dc:relation>
   <dc:rights>open access</dc:rights>
   <dc:rights>Aquest document està subjecte a una llicència d'ús Creative Commons. Es permet la reproducció total o parcial, la distribució, la comunicació pública de l'obra i la creació d'obres derivades, fins i tot amb finalitats comercials, sempre i quan es reconegui l'autoria de l'obra original.</dc:rights>
   <dc:rights>https://creativecommons.org/licenses/by/4.0/</dc:rights>
   <dc:publisher/>
</qdc:qualifieddc></metadata></record></GetRecord></OAI-PMH>